At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HCC Warrior Met Coal LLC
Pre-Mkt 01-06 05:13:43 EST
89.94
+0.39
+0.44%
High91.34Low88.79Vol613.53K
Open90.01D1 Closing89.55Amplitude2.85%
Mkt Cap4.73BTradable Cap4.63BTotal Shares52.57M
T/O55.13MT/O Rate1.19%Tradable Shares51.47M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
GlobeNewswire  ·  2025-12-26
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
GlobeNewswire  ·  2025-12-24
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
Can-Fite Provides Update on Clinical and Financial Status
GlobeNewswire  ·  2025-12-16
Can-Fite Provides Update on Clinical and Financial Status
Warrior Met Coal Is Maintained at Neutral by UBS
Dow Jones  ·  2025-12-13
Warrior Met Coal Is Maintained at Neutral by UBS
Discover 3 Stocks Priced Below Estimated Value
Simply Wall St.  ·  2025-12-09
Discover 3 Stocks Priced Below Estimated Value
Warrior Met Coal Inc : Jefferies Raises Target Price to $95 From $85
THOMSON REUTERS  ·  2025-12-08
Warrior Met Coal Inc : Jefferies Raises Target Price to $95 From $85
U.S. RESEARCH ROUNDUP- Apple, Cooper Companies, Sandisk
Reuters  ·  2025-12-08
U.S. RESEARCH ROUNDUP- Apple, Cooper Companies, Sandisk
The Bull Case For Warrior Met Coal (HCC) Could Change Following Broad-Based Surge In Steelmaking Coal Demand - Learn Why
Simply Wall St.  ·  2025-12-07
The Bull Case For Warrior Met Coal (HCC) Could Change Following Broad-Based Surge In Steelmaking Coal Demand - Learn Why
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
GlobeNewswire  ·  2025-12-06
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Lyft And 2 Other Stocks That May Be Trading Below Fair Value Estimates
Simply Wall St.  ·  2025-12-03
Lyft And 2 Other Stocks That May Be Trading Below Fair Value Estimates
Zymeworks Announces Participation in Upcoming Conferences
GlobeNewswire  ·  2025-12-03
Zymeworks Announces Participation in Upcoming Conferences
3 Prominent Stocks Estimated To Be Undervalued By At Least 40.2%
Simply Wall St.  ·  2025-12-02
3 Prominent Stocks Estimated To Be Undervalued By At Least 40.2%
How Investors May Respond To Warrior Met Coal (HCC) Surpassing Q3 Estimates and Gaining Analyst Interest
Simply Wall St.  ·  2025-11-28
How Investors May Respond To Warrior Met Coal (HCC) Surpassing Q3 Estimates and Gaining Analyst Interest
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
GlobeNewswire  ·  2025-11-26
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Warrior Met Coal (HCC) Receives a New Rating from Texas Capital Securities
TIPRANKS  ·  2025-11-25
Warrior Met Coal (HCC) Receives a New Rating from Texas Capital Securities
HENLIUS (02696): First Patient Dosed in China for International Phase 1 Clinical Study of HLX13 (Ipilimumab Biosimilar) in First-Line Treatment of Unresectable Hepatocellular Carcinoma (HCC)
Stock News  ·  2025-11-25
HENLIUS (02696): First Patient Dosed in China for International Phase 1 Clinical Study of HLX13 (Ipilimumab Biosimilar) in First-Line Treatment of Unresectable Hepatocellular Carcinoma (HCC)
Warrior Met Coal Is Maintained at Neutral by UBS
Dow Jones  ·  2025-11-24
Warrior Met Coal Is Maintained at Neutral by UBS
UBS Adjusts Price Target on Warrior Met Coal to $80 From $75, Maintains Neutral Rating
MT Newswires Live  ·  2025-11-24
UBS Adjusts Price Target on Warrior Met Coal to $80 From $75, Maintains Neutral Rating
Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
GlobeNewswire  ·  2025-11-24
Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
Warrior Met Coal Inc : UBS Raises Target Price to $80 From $75
THOMSON REUTERS  ·  2025-11-24
Warrior Met Coal Inc : UBS Raises Target Price to $80 From $75

Introduction

Company Name.
Warrior Met Coal LLC
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Warrior Met Coal, Inc. produces and exports non-thermal metallurgical coal for the steel industry. It operates two underground mines located in Alabama. The company sells its metallurgical coal to a customer base of blast furnace steel producers located primarily in Europe, South America, and Asia. It also sells natural gas, which is extracted as a byproduct from coal production. Warrior Met Coal, Inc. was incorporated in 2015 and is headquartered in Brookwood, Alabama.
Issue price:
--